CAMP4 Therapeutics closes second tranche of private placement, raising $50.1 million

CAMP4 Therapeutics Corporation announced on August 4, 2026 that it had closed the second tranche of a private placement first disclosed in September 2025. The company received about $50.1 million in gross proceeds by selling 10,756,498 shares priced at $1.53 each, plus 39,306 shares at $1.65 per share to certain directors, employees and consultants, and 21,925,368 pre-funded warrants priced at $1.5299 each in lieu of common stock.¹

CAMP4 said it plans to use the proceeds to continue developing CMP-002, for which it had recently gained clearance from Australia's Therapeutic Goods Administration and a local Human Research Ethics Committee to start a Phase 1/2 trial in SYNGAP1-related disorder, along with funding its earlier-stage pipeline.¹

Participants in the second closing included Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and CURE SYNGAP1.¹ Leerink Partners served as lead placement agent, with Piper Sandler & Co., Cantor Fitzgerald & Co. and Wedbush Securities Inc. acting as co-placement agents.¹

According to the company's related 8-K filing, CAMP4 announced in July 2026 that it had received the Australian regulatory clearance, satisfying a milestone under the original purchase agreement, and also received a price threshold waiver, which triggered the second closing.¹ On August 3, 2026, CAMP4 and certain investors amended the original agreement to adjust mechanics for the second closing, which occurred that same day.¹

The pre-funded warrants carry an exercise price of $0.0001 per share, do not expire, can be exercised on a cashless basis, and are capped at a beneficial ownership limit not exceeding 19.99%.¹